¼¼°èÀÇ ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : Á¾·ùº°, ÀûÀÀÁõ¡¤°ø±Þ¿øº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2025-2032³â)
Recombinant Protein Therapeutics CDMO Market, By Type, By Indication, By Source, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
»óǰÄÚµå : 1684413
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 316 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå ±Ô¸ð´Â 2024³â 209¾ï 2,032¸¸ ´Þ·¯·Î 2025³âºÎÅÍ 2032³â±îÁö CAGR 13.98%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå ¿ªÇÐ

»ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå °³Ã´ÀÌ ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀåÀÇ ¼ºÀåÀº »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Á¦Á¶ÀÇ º¹À⼺ÀÌ °áÇÕÇÏ¿© Á¦¾àȸ»ç¿Í »ý¸í°øÇÐ ±â¾÷µéÀÌ Àü¹® CDMO¿¡ ÀÇÁ¸ÇÏ°Ô µÈ ¹è°æ¿¡ ±âÀÎÇÕ´Ï´Ù. ¿À¸®Áö³Î ¹ÙÀÌ¿ÀÀǾàǰÀÇ ºñ¿ë È¿À²ÀûÀÎ ¹öÀüÀÎ ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ½ÃÀå¿¡¼­ ¹Þ¾Æµé¿©Áö°í ÀÖÀ¸¸ç, ÀÌ´Â ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ¹ÙÀÌ¿À¸®¾×ÅÍ, ¿¬¼Ó »ý»ê, °í¼öÀ² ¹ßÇö ½Ã½ºÅÛ(CHO ¼¼Æ÷, HEK293 ¼¼Æ÷ µî)À» ÅëÇØ ´Ü¹éÁú »ý»ê È¿À²ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¾÷½ºÆ®¸² ¹× ´Ù¿î½ºÆ®¸² °øÁ¤ÀÇ ±â¼ú Çõ½ÅÀº ´Ü¹éÁú ¼öÀ²À» Çâ»ó½Ã۰í Àüü »ý»ê ºñ¿ë°ú »ý»ê ±â°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù.

¸ÂÃãÀÇ·á¿Í Á¤¹ÐÄ¡·áÀÇ ºÎ»óÀ¸·Î ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ ´Ü¹éÁúÀ» ±â¹ÝÀ¸·Î ÇÑ ¼¼Æ÷ Ä¡·á¿Í À¯ÀüÀÚ Ä¡·á´Â ÷´Ü »ý¹°ÇÐÀû Á¦Á¦¿¡¼­ CDMOÀÇ ¿ªÇÒÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¾¾çÇÐ, Èñ±ÍÁúȯ, Àç»ýÀÇÇÐ ºÐ¾ßÀÇ »õ·Î¿î ÀÀ¿ë ºÐ¾ß°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾ç, ƯÈ÷ Áß±¹, Àεµ, Çѱ¹Àº Àú·ÅÇÑ ºñ¿ë°ú Á¤ºÎ Áö¿ø Á¤Ã¥À¸·Î ÀÎÇØ ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ÀÇ °ÅÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¸¹Àº CDMOµéÀÌ Àú·ÅÇÑ °¡°ÝÀÇ ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ À̵é Áö¿ª¿¡ ½Ã¼³À» ¼³¸³Çϰí ÀÖ½À´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È ¾à 13.98%ÀÇ CAGR·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

À¯Çüº°·Î´Â ÀÎÅÍÆä·Ð ºÎ¹®ÀÌ °¨¿°¼º ÁúȯÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ 2024³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¾ú½À´Ï´Ù.

ÀûÀÀÁõº°·Î´Â À¯º´·üÀÌ ³ôÀº ÁúȯÀ¸·Î ÀÎÇÑ ´Ü¹éÁú Ä¡·áÁ¦¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä·Î ÀÎÇØ 2024³â¿¡´Â ±âŸ ºÎ¹®ÀÌ ÁÖ¿ä ÀûÀÀÁõ ºÎ¹®À¸·Î ºÎ»óÇß½À´Ï´Ù.

°ø±Þ¿øº°·Î´Â Æ÷À¯·ù ½Ã½ºÅÛ ºÎ¹®ÀÌ Àΰ£ ´ç´Ü¹éÁú¿¡ ´ëÇÑ ³ôÀº Àû¿ëÀ¸·Î ÀÎÇØ 2024³â °ø±Þ¿ø ºÎ¹®ÀÌ ¼±µÎ¸¦ Â÷ÁöÇß½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ÁÖ¿ä ¼öÀÍ¿øÀ̾ú½À´Ï´Ù. ÀÌ´Â Á¤ºÎÀÇ Áö¿ø Á¤Ã¥°ú ¿î¼Û ºÐ¾ßÀÇ ¹ßÀüÀ¸·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ¼¼°è ½ÃÀåÀº À¯Çü, ÀûÀÀÁõ, °ø±Þ¿ø, Áö¿ª¿¡ µû¶ó ºÐ·ùµË´Ï´Ù.

½ÃÀåÀº Á¾·ùº°·Î ¼ºÀåÈ£¸£¸ó, ÀÎÅÍÆä·Ð, ¹é½Å, ¸é¿ªÁõ°­Á¦, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â °ÍÀº ÀÎÅÍÆä·ÐÀÔ´Ï´Ù. ÁÖ·Î °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡°¡ ÀÌ ºÐ¾ßÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÀûÀÀÁõº°·Î ¾Ï, °¨¿°Áúȯ, ¸é¿ªÁúȯ, ´ë»çÁúȯ, Ç÷¾×Áúȯ, ±âŸ 6°¡Áö·Î ºÐ·ùµË´Ï´Ù. ±âŸ ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ºÐ¾ß´Â ´ë»ç¼º Áúȯ ºÐ¾ßÀÔ´Ï´Ù.

ÀÌ ½ÃÀåÀº °ø±Þ¿ø¿¡ µû¶ó Æ÷À¯·ù ½Ã½ºÅÛ, ¹Ì»ý¹° ½Ã½ºÅÛ, ±âŸÀÇ ¼¼ °¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù. °ø±Þ¿øº°·Î´Â Æ÷À¯·ù ½Ã½ºÅÛÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. »ý¹°ÇÐÀû ¾à¹°, À¯Àü°øÇп¡ ´ëÇÑ Àû¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : Áö¿ªº° ºÐ¼®

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå¿¡¼­´Â ºÏ¹Ì°¡ µÎµå·¯Áø À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹Àº ÀçÁ¶ÇÕ ´Ü¹éÁú ÀǾàǰ »ý»ê¿¡ ÀÖ¾î ¼¼°èÀûÀÎ ¼±µÎÁÖÀÚ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ÀÇ °­·ÂÇÑ R&D ÀÎÇÁ¶ó¿Í Àß °®ÃçÁø ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶ ¿ª·®ÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå¿¡¼­ Å« ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ÅõÀÚ È®´ë µîÀÌ ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«´Â ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀåÀÌ ¿Ï¸¸ÇÏ°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : °æÀï »óȲ

½ÃÀå ÁøÀÔ ±â¾÷µéÀº ÀçÁ¶ÇÕ ´Ü¹éÁúÀ» Æ÷ÇÔÇÑ ¹ÙÀÌ¿ÀÀǾàǰÀÇ °³¹ß ¹× Á¦Á¶¿¡ °üÇÑ Á¾ÇÕÀûÀÎ ¼­ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀϺδ ġ·á¿ë ´Ü¹éÁúÀÇ °³¹ß ¹× Á¦Á¶¸¦ Àü¹®À¸·Î Çϸç, ¼¼Æ÷ÁÖ °³¹ßºÎÅÍ »ó¾÷Àû »ý»ê±îÁö ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ±â¾÷µµ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMOÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : »ê¾÷ ºÐ¼®

Á¦5Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : ³ô¾ÆÁö´Â ÁöÁ¤ÇÐÀû ±äÀåÀÇ ¿µÇâ

Á¦6Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå »óȲ

Á¦7Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : Á¾·ùº°

Á¦8Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : ÀûÀÀÁõº°

Á¦9Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : °ø±Þ¿øº°

Á¦10Àå ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ½ÃÀå : Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® : ÀçÁ¶ÇÕ ´Ü¹éÁú Ä¡·áÁ¦ CDMO ¾÷°è

Á¦12Àå AnalystViewÀÇ Àü¹æÀ§Àû ºÐ¼®

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Recombinant protein therapeutics CDMO Market size was valued at USD 20,920.32 Million in 2024, expanding to a CAGR of 13.98% from 2025 to 2032.

Recombinant protein therapeutics CDMO is specialized in recombinant protein therapeutics that provides services to biotech and pharmaceutical companies for the development, production, and scaling of protein-based drugs. These companies help in the end-to-end process, including cell line development, upstream and downstream processing, analytical testing, regulatory compliance, and large-scale manufacturing.

Recombinant protein therapeutics CDMO Market- Market Dynamics

Increasing demand for biologics and development in bioprocessing technologies are expected to propel market demand

The recombinant protein therapeutics CDMO market growth is driven by increasing demand for biologics, combined with the complexity of their production, has driven pharmaceutical and biotech companies to rely on specialized CDMOs. Biosimilars, which are cost-effective versions of original biologics, are gaining market acceptance, further driving the demand for CDMO services in recombinant protein production, boosting market growth. Single-use bioreactors, continuous manufacturing, and high-yield expression systems (such as CHO and HEK293 cells) have enhanced the efficiency of protein production. Innovations in upstream and downstream processing have improved protein yields, reducing overall production costs and timelines.

The rise of personalized medicine and precision therapeutics has increased demand for customized recombinant proteins. Recombinant protein-based cell and gene therapies are expanding the role of CDMOs in advanced biologics. Further, emerging applications in oncology, rare diseases, and regenerative medicine are fueling market growth. Asia-Pacific, particularly China, India, and South Korea, is becoming a hub for biopharmaceutical manufacturing due to lower costs and supportive government policies. Thus, many CDMOs are setting up facilities in these regions to cater to the growing demand for affordable biologics.

Recombinant protein therapeutics CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 13.98% over the forecast period (2025-2032)

Based on Type segmentation, the interferons segment was predicted to show maximum market share in the year 2024, due to high prevalence of infectious diseases.

Based on Indication segmentation, the others segment was the leading Indication segment in 2024, due to the high demand for protein therapeutics due to high prevalence disorders.

Based on Source segmentation, the mammalian systems segment was the leading Source segment in 2024, due to their high applications in human glycoproteins.

On the basis of region, Norh America was the leading revenue generator in 2024, owing to supportive government policies & development in transportation sector.

Recombinant protein therapeutics CDMO Market- Segmentation Analysis:

The Global Recombinant protein therapeutics CDMO Market is segmented on the basis of Type, Indication, Source, and Region.

The market is divided into five categories based on Type: growth hormones, interferons, vaccines, immunostimulant agents, and others. The interferons segment dominates the market. The increasing prevalence of infectious disorders is mainly spurring segment growth.

The market is divided into six categories based on Indication: oncology, infectious diseases, immunological disorders, metabolic disorders, hematological disorders, and others. The others segment is expected to hold the largest share. The metabolic disorders segment is expected to grow at the fastest rate over the forecast period.

The market is divided into three categories based on Source: mammalian system, microbial systems, and others. The mammalian systems segment holds the largest share of the source segment. The increasing applications biological drugs, genetical engineering are anticipated to bolster market growth.

Recombinant protein therapeutics CDMO Market- Geographical Insights

Across the world, the Recombinant protein therapeutics CDMO market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a prominent position in the recombinant protein therapeutics CDMO market. The United States has established itself as a global leader in the production of recombinant protein drugs. The country's strong research and development infrastructure and well-developed biopharmaceutical manufacturing capabilities contribute to market growth. The Asia-Pacific region is poised for significant growth in the recombinant protein therapeutics CDMO market. Factors contributing to this include a rising prevalence of chronic diseases, increased healthcare expenditures, and growing investments in biotechnology are offering growth opportunities. The Middle East and Africa are experiencing moderate growth in the recombinant protein therapeutics CDMO market.

Recombinant protein therapeutics CDMO Market- Competitive Landscape:

The recombinant protein therapeutics CDMO market is characterized by intense competition, with several key players striving to enhance their service offerings and expand their market presence. market participants offer a comprehensive range of services for the development and manufacture of biopharmaceuticals, including recombinant proteins. Some of the companies specialize in the development and manufacturing of therapeutic proteins, providing services from cell line development to commercial production.

Recent Developments:

In 2024, Novo Holdings announced a USD 16.5 billion acquisition of Catalent, planning to expand production capabilities for its successful weight-loss drugs.

In June 2023, Richter-Helm BioLogics announced the plan for the development of a production site in Bovenau, Europe.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET KEY PLAYERS

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY SOURCE- MARKET ANALYSIS, 2019-2032

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

Table of Contents

1. Recombinant Protein Therapeutics CDMO Market Overview

2. Executive Summary

3. Recombinant Protein Therapeutics CDMO Key Market Trends

4. Recombinant Protein Therapeutics CDMO Industry Study

5. Recombinant Protein Therapeutics CDMO Market: Impact of Escalating Geopolitical Tensions

6. Recombinant Protein Therapeutics CDMO Market Landscape

7. Recombinant Protein Therapeutics CDMO Market - By Type

8. Recombinant Protein Therapeutics CDMO Market - By Indication

9. Recombinant Protein Therapeutics CDMO Market - By Source

10. Recombinant Protein Therapeutics CDMO Market- By Geography

11. Key Vendor Analysis- Recombinant Protein Therapeutics CDMO Industry

12. 360 Degree AnalystView

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â